Anti-Streptolysin O ELISA Kit

Sample

Serum and plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

The ELISA kit is an enzyme immunoassay for the quantitative determination of Anti-Streptolysin O in human serum and plasma.

Contents of Kit

1. Specimen Dilution Buffer – DIL 5x
1 vial, containing 40 ml dilution buffer 5x concentrated. Contains 0.09 % NaN₃ and antimicrobial agents and an inert green dye.
2. Washing Solution - WASH 20x
1 vial containing 50 ml 20x concentrated phosphate buffered washing solution.
3. Chromogen Solution - CHROM
1 vial, containing 15 ml of a solution containing H2O2 and tetramethylbenzidine.
4. Stopping Solution - STOP
1 vial, containing 12 ml of 0.5M H₂SO₄.
5. Coated Microtiter strips - MTP
12 x 8 well strips coated with Streptolysin O. 6a-6e. Standard Sera – CAL N
5 vials, each containing 1/10 prediluted ASLO standard solutions (0.5 ml), N having following values:
CAL 0: 0 IU/ml; CAL 100: 100 IU/ml; CAL 200: 200 IU/ml; CAL 400: 400 IU/ml; CAL 800: 800 IU/ml. Contain 0,09 % NaN₃.
7. Conjugate - CONJ
1 vial, containing peroxidase conjugated anti-human IgG antibodies (12 ml). Contains antimicrobial agents and an inert red dye.
8. Control Sample –CTL
1 vial, containing positive serum (0.1 ml). Target value is indicated on the label of the vial. Contains 0,09 % NaN₃.

Storage

1. Store the microtiter strips in their original packaging with the desiccant until all the strips have been used.
2. Never use any kit components beyond the expiration date.
3. Do not expose Chromogen Solution (3) to strong light or high temperature during storage. This solution should be colourless; if not, it should be replaced.

Performance Characteristics

The minimal detectable concentration is approx. 8 IU/ml.

General Description

The serum titers of anti-streptolysin O (ASLO) may be of important diagnostic value in patients having a recent streptococcal group A infection, since the sequels of such infections include rheumatic
fever, glomerulonephritis and erythema nodosum. Increased titers of ASLO develop after the second week of infection and reach a peak in 4 to 6 weeks: this peak usually occurs shortly after the onset of rheumatic fever.
ASLO is present in most individuals in low titers since streptococcal infections are common. Therefore, comparison of ASLO-titers at (bi-)weekly intervals yields more valuable information than a single determination. Elevated or increasing ASLO titers are indicative of recent infection.